In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rapid HIV Testing: How Big a Market, Really?

Executive Summary

OraSure Technologies is first (with the exception of an outdated, complicated test sold by Abbott) to get coveted FDA approval for a rapid HIV diagnostic test, and it also won a hard-to-get CLIA waiver for the test after a one-day review by the Department of Health and Human Services; the waiver enables the test to be used in a much wider variety of non-laboratory settings. The company's opportunity looks huge, but the test's success is far from a sure bet.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts